JP2020516293A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020516293A5 JP2020516293A5 JP2019555915A JP2019555915A JP2020516293A5 JP 2020516293 A5 JP2020516293 A5 JP 2020516293A5 JP 2019555915 A JP2019555915 A JP 2019555915A JP 2019555915 A JP2019555915 A JP 2019555915A JP 2020516293 A5 JP2020516293 A5 JP 2020516293A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- optionally
- deletion
- nucleotides
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002773 nucleotide Substances 0.000 claims 60
- 125000003729 nucleotide group Chemical group 0.000 claims 60
- 238000012217 deletion Methods 0.000 claims 41
- 230000037430 deletion Effects 0.000 claims 41
- 241000701161 unidentified adenovirus Species 0.000 claims 29
- 206010028980 Neoplasm Diseases 0.000 claims 13
- 108700019146 Transgenes Proteins 0.000 claims 11
- 230000001225 therapeutic effect Effects 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 9
- -1 CD86 Proteins 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 101000852980 Homo sapiens Interleukin-23 subunit alpha Proteins 0.000 claims 4
- 101000894428 Homo sapiens Transcriptional repressor CTCFL Proteins 0.000 claims 4
- 101001049954 Human adenovirus C serotype 2 Early 4 ORF6 protein Proteins 0.000 claims 4
- 102100021393 Transcriptional repressor CTCFL Human genes 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 238000003776 cleavage reaction Methods 0.000 claims 4
- 230000007017 scission Effects 0.000 claims 4
- 230000004614 tumor growth Effects 0.000 claims 4
- 102000004961 Furin Human genes 0.000 claims 3
- 108090001126 Furin Proteins 0.000 claims 3
- 102100036705 Interleukin-23 subunit alpha Human genes 0.000 claims 3
- 102100036678 Interleukin-27 subunit alpha Human genes 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 3
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 3
- 230000000977 initiatory effect Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000006337 proteolytic cleavage Effects 0.000 claims 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 238000011144 upstream manufacturing Methods 0.000 claims 3
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 claims 2
- 206010061424 Anal cancer Diseases 0.000 claims 2
- 208000007860 Anus Neoplasms Diseases 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 102100032937 CD40 ligand Human genes 0.000 claims 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 2
- 206010062878 Gastrooesophageal cancer Diseases 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 claims 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims 2
- 101000864646 Homo sapiens Dickkopf-related protein 1 Proteins 0.000 claims 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 2
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 claims 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 2
- 102000008070 Interferon-gamma Human genes 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 108010002352 Interleukin-1 Proteins 0.000 claims 2
- 102100036712 Interleukin-27 subunit beta Human genes 0.000 claims 2
- 108010002386 Interleukin-3 Proteins 0.000 claims 2
- 108090000978 Interleukin-4 Proteins 0.000 claims 2
- 108010002616 Interleukin-5 Proteins 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 108090001007 Interleukin-8 Proteins 0.000 claims 2
- 108010002335 Interleukin-9 Proteins 0.000 claims 2
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims 2
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 2
- 108700026226 TATA Box Proteins 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 2
- 206010057644 Testis cancer Diseases 0.000 claims 2
- 102000006601 Thymidine Kinase Human genes 0.000 claims 2
- 108020004440 Thymidine kinase Proteins 0.000 claims 2
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims 2
- 229960004373 acetylcholine Drugs 0.000 claims 2
- 201000011165 anus cancer Diseases 0.000 claims 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 201000006974 gastroesophageal cancer Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 230000003463 hyperproliferative effect Effects 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 229960003130 interferon gamma Drugs 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 238000012737 microarray-based gene expression Methods 0.000 claims 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 2
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 201000003120 testicular cancer Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 101710113110 B-cell receptor-associated protein 31 Proteins 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 101710127257 E4-ORF1 Proteins 0.000 claims 1
- 101000852998 Homo sapiens Interleukin-27 subunit alpha Proteins 0.000 claims 1
- 101000852964 Homo sapiens Interleukin-27 subunit beta Proteins 0.000 claims 1
- 101710139711 IkB-like protein Proteins 0.000 claims 1
- 108050003558 Interleukin-17 Proteins 0.000 claims 1
- 101710081123 Interleukin-27 subunit alpha Proteins 0.000 claims 1
- 101710116301 Interleukin-27 subunit beta Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 1
- 101100012019 Mus musculus Etv4 gene Proteins 0.000 claims 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 101710193132 Pre-hexon-linking protein VIII Proteins 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 210000002288 golgi apparatus Anatomy 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 239000000833 heterodimer Substances 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 102000003898 interleukin-24 Human genes 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000000716 merkel cell Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 230000006798 recombination Effects 0.000 claims 1
- 238000005215 recombination Methods 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762484841P | 2017-04-12 | 2017-04-12 | |
| US62/484,841 | 2017-04-12 | ||
| PCT/US2018/027375 WO2018191545A1 (en) | 2017-04-12 | 2018-04-12 | Multiple transgene recombinant adenovirus |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020516293A JP2020516293A (ja) | 2020-06-11 |
| JP2020516293A5 true JP2020516293A5 (enExample) | 2021-05-27 |
| JP7301748B2 JP7301748B2 (ja) | 2023-07-03 |
Family
ID=63792941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019555915A Active JP7301748B2 (ja) | 2017-04-12 | 2018-04-12 | 複数トランスジーン組み換えアデノウイルス |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12036247B2 (enExample) |
| EP (1) | EP3610025A4 (enExample) |
| JP (1) | JP7301748B2 (enExample) |
| KR (1) | KR20200006058A (enExample) |
| CN (1) | CN110914440A (enExample) |
| EA (1) | EA201990822A1 (enExample) |
| WO (1) | WO2018191545A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2903582C (en) | 2013-03-14 | 2021-06-08 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
| JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| CA3045892A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| BR112020019942A2 (pt) | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | composições de adenovírus oncolítico com propriedades de replicação aprimoradas |
| WO2022007800A1 (zh) * | 2020-07-06 | 2022-01-13 | 嘉兴安宇生物科技有限公司 | 一种非洲猪瘟的重组腺病毒疫苗及其构建方法 |
| CN116621965A (zh) * | 2022-05-06 | 2023-08-22 | 珠海丽凡达生物技术有限公司 | 治疗性核酸分子、混合物、药物及在治疗实体瘤中的应用 |
| EP4554559A1 (en) | 2022-07-13 | 2025-05-21 | EpicentRx, Inc. | Adenoviral vectors encapsulated in cationic liposomes, and preparation and use thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5670488A (en) * | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| AUPN477695A0 (en) | 1995-08-14 | 1995-09-07 | Commonwealth Scientific And Industrial Research Organisation | Gene therapy |
| GB9626029D0 (en) | 1996-12-14 | 1997-01-29 | Univ Leeds | EVH-1 vectors |
| US20040234505A1 (en) | 1998-09-23 | 2004-11-25 | Stuart Naylor | Polynucleotide constructs and uses thereof |
| CN1183250C (zh) | 2000-12-01 | 2005-01-05 | 卫健生物科技有限公司 | 高效表达肿瘤血管生成抑制因子的肿瘤细胞内特异性增殖的病毒及其构建方法 |
| AU2002256388A1 (en) | 2001-04-30 | 2002-11-11 | Cell Genesys, Inc. | Viral-mediated delivery and in vivo expression of polynucleotides encoding anti-angiogenic proteins |
| US20050136035A1 (en) | 2003-06-03 | 2005-06-23 | Derek Ko | Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site |
| US7709224B2 (en) | 2003-06-03 | 2010-05-04 | Biosante Pharmaceuticals, Inc. | Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site |
| US7473418B2 (en) | 2004-03-25 | 2009-01-06 | Cell Genesys, Inc. | Pan cancer oncolytic vectors and methods of use thereof |
| AU2006203736B2 (en) | 2004-12-31 | 2012-03-29 | Per Sonne Holm | Method for reversing multiple resistance in animal cells |
| KR100911624B1 (ko) * | 2007-05-14 | 2009-08-12 | 연세대학교 산학협력단 | Ｉｌ－１２ 및 ｉｌ－２３의 효율적인 공동발현 방법 |
| KR100896483B1 (ko) | 2007-07-13 | 2009-05-08 | 연세대학교 산학협력단 | Ｉｌ-12 및 4-1ｂｂｌ을 발현하는 종양 선택적 살상 재조합아데노바이러스 및 수지상 세포를 유효성분으로 포함하는항종양용 약제학적 조성물 |
| PT2403951E (pt) * | 2009-03-02 | 2016-01-29 | Univ California | Mutantes de adenovírus e1a e e1b de tumores |
| JP2013527753A (ja) | 2010-03-23 | 2013-07-04 | イントレキソン コーポレーション | 治療タンパク質を条件的に発現するベクター、該ベクターを含む宿主細胞およびそれらの使用 |
| KR101253276B1 (ko) | 2010-07-27 | 2013-04-10 | 윤채옥 | 복합 유전자 치료용 항종양 조성물 |
| EP2619312A1 (en) | 2010-09-24 | 2013-07-31 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies |
| SG10201913795TA (en) | 2012-02-02 | 2020-03-30 | Univ Texas | Adenoviruses expressing heterologous tumor-associated antigens |
| WO2014170389A1 (en) * | 2013-04-18 | 2014-10-23 | Tilt Biotherapeutics Oy | Enhanced adoptive cell therapy |
| CN103614416B (zh) | 2013-09-30 | 2016-09-07 | 中国人民解放军第二军医大学东方肝胆外科医院 | 一种携带人穿膜肽p53与GM-CSF基因的重组溶瘤腺病毒及其用途 |
| KR102365331B1 (ko) | 2014-05-28 | 2022-02-22 | 고꾸리츠 다이가꾸 호우징 오까야마 다이가꾸 | Reic 유전자를 발현하는 제한 증식형 아데노바이러스 |
| DK3198009T3 (da) | 2014-09-24 | 2021-11-22 | Salk Inst For Biological Studi | Onkolytiske tumorvira og anvendelsesfremgangsmåder |
| WO2018083259A1 (en) * | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| US10232053B2 (en) | 2016-12-30 | 2019-03-19 | Trieza Therapeutics, Inc. | Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer |
| SG11201906973TA (en) | 2017-01-30 | 2019-08-27 | Epicentrx Inc | Multiple transgene recombinant adenovirus |
| EP3630959A4 (en) | 2017-05-24 | 2021-03-17 | EpicentRx, Inc. | ANTI-ANGIOGENIC ADENOVIRUS |
-
2017
- 2017-09-27 EA EA201990822A patent/EA201990822A1/ru unknown
-
2018
- 2018-04-12 US US16/604,675 patent/US12036247B2/en active Active
- 2018-04-12 JP JP2019555915A patent/JP7301748B2/ja active Active
- 2018-04-12 EP EP18784495.6A patent/EP3610025A4/en not_active Withdrawn
- 2018-04-12 KR KR1020197033395A patent/KR20200006058A/ko active Pending
- 2018-04-12 CN CN201880038592.2A patent/CN110914440A/zh active Pending
- 2018-04-12 WO PCT/US2018/027375 patent/WO2018191545A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020516293A5 (enExample) | ||
| JP2020505049A5 (enExample) | ||
| Xiao et al. | Trefoil factors: Gastrointestinal-specific proteins associated with gastric cancer | |
| Keller et al. | Mechanisms of impaired differentiation in rhabdomyosarcoma | |
| KR102164876B1 (ko) | ＩＬ12 및 ｓｈＶＥＧＦ 동시발현 아데노바이러스를 포함하는 항종양 면역성 증진 조성물 | |
| WO2008140621A3 (en) | Transgenic oncolytic viruses and uses thereof | |
| JP2014207903A5 (enExample) | ||
| JP7438552B2 (ja) | 注射用医薬品、注射用調製物、および注射用医薬品の製造における使用 | |
| JP2007511216A5 (enExample) | ||
| JP2020516277A5 (enExample) | ||
| CN110741080A (zh) | 多转基因重组腺病毒 | |
| JP2020505046A5 (enExample) | ||
| EP1678193B1 (en) | Hepatocellular carcinoma specific promoter and uses thereof | |
| JP2020516293A (ja) | 複数トランスジーン組み換えアデノウイルス | |
| Krill et al. | Exploring the therapeutic rationale for angiogenesis blockade in cervical cancer | |
| Shen et al. | Specific CEA-producing colorectal carcinoma cell killing with recombinant adenoviral vector containing cytosine deaminase gene | |
| CN105121635B (zh) | 突变型痘苗病毒株、其用途及其制造方法 | |
| IL292788B2 (en) | Multivalent pd-l1 binding compounds for treating cancer | |
| CN103484462B (zh) | Survivin启动子调控CD基因的重组腺病毒载体构建及其应用 | |
| Lu et al. | Locked and loaded: engineering and arming oncolytic adenoviruses to enhance anti-tumor immune responses | |
| Todryk et al. | Can immunotherapy by gene transfer tip the balance against colorectal cancer? | |
| Kwon et al. | Vitamin D3 up-regulated protein 1 controls the priming phase of liver regeneration | |
| JP2025500867A (ja) | 前立腺癌ワクチン及びその使用 | |
| KR100357054B1 (ko) | 종양 특이증식 재조합 아데노바이러스 및 그를 이용하여 종양세포만을 특이적으로 형질전환시키는 방법 | |
| EP2752429B1 (en) | Fusion protein comprising circularly permuted form of trail/apo2l, coding gene and use thereof |